Literature DB >> 7717328

Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine.

H Schwörer1, H Münke, F Stöckmann, G Ramadori.   

Abstract

A 69-yr-old man with known carcinoid syndrome treated with octreotide and interferon-alpha 2b developed diarrhea, with six to eight watery to semiliquid stools per day. Diminished stool frequency and increased stool consistency were obtained by treatment with the 5-hydroxytryptamine-3 receptor antagonists ondansetron and tropisetron. Successful alleviation of the diarrhea was also observed with the alpha 2-receptor agonist clonidine. These observations indicate that these classes of drugs should be evaluated in a controlled trial in patients with carcinoid-associated diarrhea.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7717328

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

1.  Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial.

Authors:  G Stacher; U Weber; G Stacher-Janotta; P Bauer; K Huber; A Holzäpfel; G Krause; C Steinborn
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

Review 2.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

3.  What about clonidine for diarrhoea? A systematic review and meta-analysis of its effect in humans.

Authors:  Konstantinos C Fragkos; Natalia Zárate-Lopez; Christos C Frangos
Journal:  Therap Adv Gastroenterol       Date:  2016-01-25       Impact factor: 4.409

4.  Medium-term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea.

Authors:  S B Saslow; J S Scolapio; M Camilleri; L A Forstrom; G M Thomforde; D D Burton; J Rubin; H C Pitot; A R Zinsmeister
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.